Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 100 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: concurrent temozolomide Clear all

Conditions: Brain and Central Nervous System Tumors
Interventions: hydroxychloroquine, temozolomide, pharmacological study, Radiation; Drug · Other · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 9
States / cities: Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more

Conditions: Glioblastoma Multiforme, Gliosarcoma
Interventions: ZD6474, temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: Patrick Y. Wen, MD; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 7
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Glioblastoma Multiforme
Interventions: Radiation, Chemotherapy; Radiation · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anaplastic Astrocytoma, Central Nervous System Neoplasm, Glioblastoma, Gliosarcoma, Spinal Cord Neoplasm
Interventions: Laboratory Biomarker Analysis, Lomustine, Radiation Therapy, Temozolomide; Other · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 21 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions: Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide; Drug · Radiation · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glioblastoma
Interventions: GammaTile®, External Beam Radiation Therapy, Temozolomide; Device · Radiation · Drug
Lead sponsor: GT Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 22
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 17 more

Conditions: Brain Tumor Adult
Interventions: DRI cell therapy; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glioblastoma
Interventions: Cannabis, Temozolomide, Radiation Therapy; Drug · Radiation
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 21 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Glioblastoma Multiforme
Interventions: Radiation therapy, Temozolomide, Bevacizumab, Everolimus; Radiation · Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 13
States / cities: Huntsville, Alabama • Fort Myers, Florida • Gainesville, Georgia + 10 more

Conditions: Glioblastoma, Gliomas
Interventions: Temozolomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2017
U.S. locations: 3
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York

Conditions: Malignant Glioma, Myelosuppression
Interventions: Medical Chart Review; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Glioblastoma (GBM)
Interventions: Ketogenic Diet, Radiation therapy, Temozolomide; Dietary Supplement · Radiation · Drug
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions: 3-Dimensional Conformal Radiation Therapy, Bevacizumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment, Temozolomide; Radiation · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 324
States / cities: Mobile, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 262 more

Conditions: Glioblastoma
Interventions: Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td), GM-CSF, 111-Indium-labeling of Cells for in vivo Trafficking Studies; Biological · Drug
Lead sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Brain and Central Nervous System Tumors, Neurotoxicity
Interventions: temozolomide, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 168
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 117 more

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: Disulfiram, Copper gluconate, Temozolomide; Drug · Dietary Supplement
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Glioblastoma Multiforme, Astrocytoma, Grade IV
Interventions: Personalized peptide vaccine, Poly-ICLC, Temozolomide; Biological · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glioblastoma, Gliosarcoma
Interventions: Peposertib, Radiation Therapy, Resection, Temozolomide; Drug · Radiation · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Newly Diagnosed High Grade Glioma
Interventions: Temozolomide, conformal brain radiation therapy, Nivolumab, Ipilimumab, Bevacizumab, 5-day Temozolomide, Lomustine, Nivolumab monotherapy; Drug · Radiation
Lead sponsor: Saint John's Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Glioblastoma (GBM)
Interventions: BGB-58067; Drug
Lead sponsor: Nader Sanai; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Glioblastoma, Gliosarcoma
Interventions: Temozolomide, Depatuxizumab mafodotin, Radiation, Placebo for ABT-414; Drug · Radiation
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 68
States / cities: Phoenix, Arizona • Springdale, Arkansas • Los Angeles, California + 52 more

Conditions: Brain and Central Nervous System Tumors
Interventions: BCNU 80mg/m2, TMZ 200mg/m2, radiation therapy, CCNU, BCNU 150mg/m2, BCNU 200mg/m2, TMZ 150mg/m2 six 6-week cycles, TMZ 150mg/m2 six 8-week cycles; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2018
U.S. locations: 92
States / cities: Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more

Conditions: Glioblastoma, Gliosarcoma
Interventions: Atezolizumab, Radiation Therapy, Temozolomide; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Glioblastoma, Glioblastoma Multiforme
Interventions: External beam radiation therapy; Radiation
Lead sponsor: John M. Buatti; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Iowa City, Iowa

Search by objective public record fields.

Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors

Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide

Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Novel Gamma-Delta (γδ)T Cell Therapy for Treatment of Patients With Newly Diagnosed Glioblastoma

Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM

Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma

Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy

Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma

Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma

Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma

Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma

Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification

Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas

Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma